Bristol-Myers Squibb Company PFD CONV 2
BMYMP · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $91,912,131 | $94,200,150 | $123,870,690 | $114,761,730 |
| - Cash | $15,726,000 | $12,599,000 | $10,875,000 | $10,346,000 |
| + Debt | $51,041,000 | $50,929,000 | $51,239,000 | $51,200,000 |
| Enterprise Value | $127,227,131 | $132,530,150 | $164,234,690 | $155,615,730 |
| Revenue | $12,222,000 | $12,269,000 | $11,201,000 | $12,342,000 |
| % Growth | -0.4% | 9.5% | -9.2% | – |
| Gross Profit | $8,787,000 | $8,070,000 | $7,340,000 | $7,424,000 |
| % Margin | 71.9% | 65.8% | 65.5% | 60.2% |
| EBITDA | $4,587,000 | $3,287,000 | $4,477,000 | $2,551,000 |
| % Margin | 37.5% | 26.8% | 40% | 20.7% |
| Net Income | $2,201,000 | $1,310,000 | $2,456,000 | $72,000 |
| % Margin | 18% | 10.7% | 21.9% | 0.6% |
| EPS Diluted | 1.08 | 0.64 | 1.2 | 0.035 |
| % Growth | 68.8% | -46.7% | 3,299.4% | – |
| Operating Cash Flow | $6,311,000 | $3,917,000 | $1,954,000 | $4,439,000 |
| Capital Expenditures | -$320,000 | -$361,000 | -$260,000 | -$378,000 |
| Free Cash Flow | $5,991,000 | $3,556,000 | $1,694,000 | $4,061,000 |